DACLATASVIR: 5,602 Adverse Event Reports & Safety Profile
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
5,602
Total FAERS Reports
581 (10.4%)
Deaths Reported
1,637
Hospitalizations
5,602
As Primary/Secondary Suspect
283
Life-Threatening
91
Disabilities
Apr 13, 2016
FDA Approved
Discontinued
Status
FDA Application: 206843 ·
Patent Expires: Jun 13, 2031 · First Report: 2000 · Latest Report: 20230401
What Are the Most Common DACLATASVIR Side Effects?
#1 Most Reported
Fatigue
510 reports (9.1%)
#2 Most Reported
Hepatocellular carcinoma
419 reports (7.5%)
#3 Most Reported
Headache
411 reports (7.3%)
All DACLATASVIR Side Effects by Frequency
| Side Effect | Reports | % of Total | Deaths | Hosp. |
|---|---|---|---|---|
| Fatigue | 510 | 9.1% | 35 | 48 |
| Hepatocellular carcinoma | 419 | 7.5% | 71 | 126 |
| Headache | 411 | 7.3% | 28 | 59 |
| Hepatitis c | 400 | 7.1% | 6 | 29 |
| Drug ineffective | 385 | 6.9% | 8 | 23 |
| Treatment failure | 310 | 5.5% | 5 | 15 |
| Nausea | 287 | 5.1% | 33 | 71 |
| Anaemia | 251 | 4.5% | 42 | 108 |
| Ascites | 205 | 3.7% | 40 | 115 |
| Off label use | 199 | 3.6% | 9 | 72 |
| Insomnia | 183 | 3.3% | 12 | 26 |
| Diarrhoea | 177 | 3.2% | 24 | 49 |
| Hepatic failure | 170 | 3.0% | 86 | 65 |
| Hepatic encephalopathy | 165 | 3.0% | 48 | 101 |
| Genotype drug resistance test positive | 164 | 2.9% | 1 | 4 |
| Acute kidney injury | 148 | 2.6% | 54 | 90 |
| Pyrexia | 142 | 2.5% | 17 | 93 |
| Asthenia | 135 | 2.4% | 12 | 47 |
| Death | 135 | 2.4% | 135 | 31 |
| Dyspnoea | 126 | 2.3% | 24 | 63 |
Who Reports DACLATASVIR Side Effects? Age & Gender Data
Gender: 39.7% female, 60.3% male. Average age: 58.1 years. Most reports from: US. View detailed demographics →
Is DACLATASVIR Getting Safer? Reports by Year
| Year | Reports | Deaths | Hosp. |
|---|---|---|---|
| 2000 | 1 | 0 | 0 |
| 2012 | 8 | 0 | 7 |
| 2013 | 18 | 6 | 15 |
| 2014 | 365 | 59 | 220 |
| 2015 | 996 | 107 | 563 |
| 2016 | 1,229 | 104 | 358 |
| 2017 | 348 | 33 | 112 |
| 2018 | 54 | 9 | 17 |
| 2019 | 30 | 2 | 8 |
| 2020 | 6 | 0 | 5 |
| 2021 | 8 | 0 | 2 |
| 2022 | 6 | 0 | 4 |
| 2023 | 4 | 0 | 0 |
What Is DACLATASVIR Used For?
| Indication | Reports |
|---|---|
| Hepatitis c | 2,520 |
| Chronic hepatitis c | 2,063 |
| Product used for unknown indication | 613 |
| Hepatic cirrhosis | 140 |
| Hepatitis c virus test | 84 |
| Hepatitis c virus test positive | 31 |
| Hiv infection | 31 |
| Hepatocellular carcinoma | 25 |
| Hepatitis | 21 |
| Chronic hepatitis | 19 |
DACLATASVIR vs Alternatives: Which Is Safer?
DACLATASVIR vs DACLIZUMAB
DACLATASVIR vs DACOMITINIB
DACLATASVIR vs DACTINOMYCIN
DACLATASVIR vs DALBAVANCIN
DACLATASVIR vs DALFAMPRIDINE
DACLATASVIR vs DALTEPARIN
DACLATASVIR vs DAMOCTOCOG ALFA PEGOL
DACLATASVIR vs DANAPAROID
DACLATASVIR vs DANAZOL
DACLATASVIR vs DANICOPAN
Official FDA Label for DACLATASVIR
Official prescribing information from the FDA-approved drug label.